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Prosthetic heart valves have been commonly used to address the increasing prevalence
of valvular heart disease. The ideal prosthetic heart valve substitute should closely mimic
the characteristics of a normal native heart valve. Despite the development of various
interventions, an exemplary valve replacement does not exist. This review provides an
overview of the novel engineering valve designs and explores emergent immunologic
insights into age-dependent structural valve degeneration (SVD).
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INTRODUCTION
The increasing prevalence of valvular heart disease worldwide is a global clinical dilemma, where
the demand for interventions is expected to hit 850,000 by 2050 (1). Prosthetic heart valves have
been used to address this problem and the two commonly used basic types are: surgically implanted
mechanical heart valves (MHVs) and biological heart valves (BHVs, which can be implanted either
surgically or by a micro-invasive transcatheter approach) (2). The ideal prosthetic heart valve
substitute should closely mimic the characteristics of a normal native heart valve and be durable,
implantable with impeccable hemodynamics, and thromboresistant. Alas, this exemplary valve
replacement is non-existent as currently available prosthetic valves are flawed (3).
ENGINEERED DESIGNS
MHVs are composed from manufactured substance with mechanically moving parts and can
be grouped into three basic design categories: bileaflet, monoleaflet, and caged ball valves. The
long-term durability is the main advantage of MHVs, but their use is limited by substantial risks of
thrombogenicity and the requirement of lifelong anticoagulation therapies to prevent formation
of blood clots. MHVs may be obstructed by blood clots in an open or closed position causing
stenosis and/or insufficiency. The complications associated with MHVs render them less desirable
for some patients, especially in: (i) young, injury-prone individuals, (ii) pregnant or menstruating
females, and (iii) patients in the developing world, where it can be challenging to carefully monitor
anti-coagulation (4, 5).
Over 300,000 surgical heart valve replacement operations are performed worldwide annually,
where 40–60% of these operations employ BHVs produced using glutaraldehyde-fixed animal
(bovine or porcine) tissue (6). The inauguration of BHVs in 1968 involved using an effective
valve replacement therapy as a treatment for heart valve disease. Since then, there has been a
substantial shift toward the use of BHVs compared to MHVs because BHVs are: (i) effective and
durable, particularly in older patients (>60 years); (ii) do not have thrombogenicity complications
and circumvent the problem of anti-coagulation medications (7). Currently, the most frequently
used BHVs are those derived from porcine aortic valves and calf-pericardium, which are
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preserved by glutaraldehyde fixation (3, 5). Glutaraldehyde
crosslinking prevents immunogenicity, and other methods
such as anti-mineralization can diminish cusp calcification
(8). The key advantages of BHVs over MHVs are that
they have significantly improved hemodynamic results,
lower gradients and larger aortic valve/orifice areas (9).
Furthermore, bioprostheses can be delivered using minimally-
invasive technique transcatheter aortic valve replacement
implantation/replacement (TAVI/TAVR).
Despite the numerous advantages of BHVs, they are not as
mechanically robust compared to MHVs and exhibit limited
durability in younger patients (particularly those younger than
60 years), which is a current obstacle hindering the progress of
bioprostheses. The findings from recent research conducted by
Goldstone et al. (10) suggest that MHVs may be a safer option
than BHVs for some patients, particularly in younger patients,
and should be used more. Their results suggest that BHVs have
a significantly greater probability of death in patients between
age 40–49, compared to the older age groups (50–69 and 70–
79). Although this begins to even out in the early phase for the
50–59 age group, BHVs still have a higher probability of death,
whereas in the older population (70–79 years), they are identical.
Thus, they concluded that the mortality benefit for patients who
received an MHV versus those who received a BHV continued
up to the age of 55 and 70 for aortic valve replacement and
mitral valve replacement, respectively. Careful consideration of
the patient’s age is required. Older patients are less likely to
outlive the BHV durability, whereas younger patients may prefer
to opt for BHVs to avoid committing to lifestyle changes (for
example, relying on blood thinners, lifetime commitment to a
restricted diet, and routine blood testing). BHVs would be a
preferred option for many women who desire to have children.
Modern advancements have resulted in a cutting-edge
resilient heart valve—Edwards Lifesciences R© Inspiris ResiliaTM
aortic valve, which incorporates state-of-the-art ResiliaTM bovine
pericardial bioprosthetic tissue. This valve has been reported
to exhibit anti-calcification properties, improved sustained
hemodynamic performance and durability, thus reducing the
likelihood of reoperation (11, 12). Furthermore, it has a unique
expandable frame and can be potentially used for future valve-in-
valve (ViV) procedures. However, ViV procedures can increase
the occurrence of prosthesis-patient mismatch (13–15). In the
case of early degeneration, the Inspiris ResiliaTM valve can be
replaced with a TAVI valve, thus avoiding open heart surgery
(16). The 2-year outcomes of the ongoing COMMENCE trial
(which aims to evaluate the safety and effectiveness of the
Inspiris ResiliaTM valve) revealed no SVD observations in any
of the 689 patients, and there was ameliorated breathlessness,
augmented effective orifice area, diminished mean gradient, and
lower paravalvular leak rate (12). The results of the COMMENCE
trial will be monitored carefully over the next 6 years, which will
provide better insight on the long-term durability of the Inspiris
ResiliaTM valve.
Since the first successful in-patient TAVI in 2002 performed
by Cribier, TAVI has become the preferred procedure
(as an alternative to open heart surgery) worldwide for high-
surgical-risk patients with severe symptomatic aortic stenosis
(AS) (17–19). The main advantages of TAVI is that the
micro-invasive TAVI procedures have diminished invasiveness
compared to minimally-invasive procedures, and can be
performed on the live, beating heart without the need for
extracorporeal circulation or cardiopulmonary bypass nor
aortic cross clamp. This renders TAVI favorable than MHV
and BHV prostheses as it overcomes the requirement for
temporary cardiac arrest, and improves patient recovery time
(20). Another advantage of TAVI is that the micro-invasive
procedures (commonly the transfemoral approach) can be
conducted in a completely percutaneous fashion and with local
anesthesia only, whereas minimally invasive approaches (such
as mini-sternotomy or mini-thoracotomy) for conventional
heart valve prostheses necessitate skin incision and general
anesthesia (17). Successful TAVI may reduce the requirement for
future hospitalization, but the expensive cost of the procedure
(circa £18,000) and the requirement of multidisciplinary team
and substantial equipment are important considerations (21).
Although TAVI has several advantages, the technology can result
in the following complications (which can ultimately lead to
mortality): (i) conduction defects, for example, atrioventricular
block and left bundle branch block (22, 23); (ii) permanent
pacemaker implantation—reported to occur in 8.5–25.9% of
patients undergoing TAVI within a month after the procedure
(24–28); (iii) paravalvular regurgitation (reported to affect circa
10% of patients) due to incomplete apposition of the prosthesis
with the aortic annulus, or incorrect implantation depth (29–31)
(iv) bleeding and vascular complications; (v) stroke, and (vi)
myocardial infarction (22).
Initially, TAVI was performed in high-surgical-risk AS
patients, but has gradually expanded to intermediate-surgical-
risk patients in both European and American guidelines based
on three major trials: SURTAVI (28), NOTION (32), and
PARTNER 2 (27). The additional challenge of long-term valve
durability arises when attempting to expand TAVI to younger,
low-risk patients, and is crucial to tackle due to the longer life
expectancy (33). A recent meta-analysis involving 3,484 patients
conducted by Witberg et al. (34) found that TAVR appears to
be associated with elevated mortality risk. Despite this study’s
limitations [(i) small patient population; (ii) studied a mixture
of low-intermediate-risk patients instead of entirely low-risk;
and (iii) predominant use of first generation TAVI devices],
SAVR should continue being the choice of treatment for low-
surgical-risk patients until more data is acquired. There are
ongoing trials [PARTNER 3 (NCT02675114), Evolut R low risk
(NCT02701283), and NOTION 2 (NCT02825134)] aiming to
extend the use of TAVI to low-risk patients (34, 35) by evaluating
the risk/benefit profile of TAVR. The outcome of these trials will
provide further insight to whether TAVR should be expanded to
low-risk patients.
STRUCTURAL VALVE DEGENERATION
With time, the function of many glutaraldehyde-fixed BHVs
(GBHVs) begin to deteriorate. This is known as structural valve
degeneration (SVD), which occurs over 1–2 decades for elderly
Frontiers in Cardiovascular Medicine | www.frontiersin.org 2 April 2019 | Volume 6 | Article 47
Li Upgrading a 50-Year Old Technology
patients, attributed to inflammatory/immune response and
calcification (36, 37). Calcification can cause valve obstruction,
resulting in stenosis and leaflet tearing due to the weakening of
tissues, and ultimately detachment of the leaflets, rendering the
valve dysfunctional. Thus, younger patients are generally treated
withMHVs despite their risks because of the age-dependent BHV
degeneration. The development of an efficacious prosthetic heart
valve that can be used in younger patients that does not require
anticoagulants will be a major advancement in this field.
Our knowledge of the mechanism(s) of age-dependent SVD
is incomplete, but it is known to be a multifaceted process
comprising an induced immunologic response to bioprostheses
(38). Firstly, it can be related to stress and mechanical
injury as calcification occurs in areas where stress or strain
on the tissue is greatest. The most common mechanism of
SVD of mitral bioprostheses is regurgitation as an effect
of leaflet prolapse or perforation. Degeneration of aortic
bioprostheses usually causes AS (39). Tissue calcification (passive
or phospholipid-directed) of fixed biological tissue is believed
to occur passively in the bloodstream by recruitment processes
taking advantage of calcium binding to tissue-fixed negatively-
charged phospholipids. This led to the development of anti-
calcification treatment over the past two decades, designed to
remove phospholipids. Lipid insudation and inflammation is
also a mechanism of age-dependent SVD. Finally, antibody-
dependent tissue calcification is a critical mechanism, which will
be discussed later.
Anti-calcification processing is a technology that has been
employed in the clinic and previous studies have reported
their preferred anti-calcification methods. Carpentier et al.
(40) reduced the phosphate content in the tissue by blocking
calcification binding sites with magnesium ions and/or with a
surfactant (Edwards XenoLogic Tween 80, Ethanol) to reduce
the rate of calcification. Vyavahere and colleagues studied
glutaraldehyde-crosslinked porcine aortic valve cusps and found
that ethanol (St. Jude α-Oleic acid) pretreatment of BHV cusps
significantly altered the material, rendering it unfavorable for
lipid adsorption (41). Jones et al. (42) assessed the effects
of several surfactants, where they found that sodium dodecyl
sulfate (Medtronic T6) significantly diminished calcification
and only in porcine aortic valvular bioprostheses. Post-fixation
processing to remove phospholipids has been widely adopted
in current commercial BHVs. Importantly, there is no flawless
animal model and these previous studies have been performed
in juvenile sheep (43, 44), where they fixated on the valve
calcification and neglected valve inflammation. Although anti-
calcification processing significantly reduces calcification in
animal models (such as sheep in these studies), it does not
diminish the incidence of SVD in younger patients. Thus, it
has not been successfully translated or made the same beneficial
impact into the clinic to resolve early SVD (10, 45).
The success of clinical cardiac xenotransplantation has
been hindered by the immunogenicity predicament. Although
glutaraldehyde fixation is established to reduce immunogenicity
and degeneration of heart valve prostheses, immunogenicity
(which may trigger calcification) is not abolished (6). This
hurdle exists because fixation eliminates the immunogenicity of
protein antigens, but, immunogenic xenogeneic carbohydrate
antigens persist (6, 7). It is well-established that the paramount
antigen is galactose-α1,3-galactose (Gal), which stimulates
xenograft rejection of tissue organs from pigs or cows by
non-human primates/humans (46). Humans and Old World
non-human primates (NHP) do not synthesize α-Gal. Instead,
they synthesize large quantities of anti-Gal antibodies, which
recognize the Gal antigens on the surface of pig cells (47–49).
This immune response results in hyperacute immune xenograft
rejection (50).
Lila et al. (7) compared the calcium content of α-Gal-positive
and GTKO pig pericardium after subcutaneous implantation
during 1 month and identified that α-Gal antigens play a
role in BHV calcification. Pericardium that was fixed only
with glutaraldehyde exhibited significantly lower calcification
levels in GTKO pigs compared with that of α-Gal-positive
pigs. Furthermore, glutaraldehyde-fixed pig pericardium
decreased calcification levels after formaldehyde, ethanol
and Tween 80 (FET) treatment (7). Lila et al. demonstrated
that glutaraldehyde-fixed pig pericardium followed by FET
treatment and pre-incubation with human anti-Gal Abs
exhibited remarkably higher α-Gal-positive pig pericardium.
Thus, anti-gal antibody (present in all humans) promotes
calcification of wild-type tissue, but not GTKO tissue, even after
treatment with anti-calcification processing (7). Another finding
was that glutaraldehyde-fixed pig pericardium followed by FET
treatment and pre-incubated with human anti-Gal antibodies
resulted in significantly increased calcification levels in α-Gal
positive pig pericardium compared with GTKO pig pericardium.
Thus, there is ample evidence that Gal antigens are a main
immune barrier to xenotransplantation (51) and are present on
commercially-available GBHVs causing accelerated calcification
and degeneration of GBHVs (38, 52–54), and it is likely that
the gal antigen is present on TAVIs. Therefore, TAVIs are not
tackling the age-dependent SVD problem, nevertheless, they have
the advantage of micro-invasive percutaneous placement. Gal
antigens can be eliminated by genetic engineering and there is
growing interest in utilizing Gal-free animal tissues from GTKO
pigs to develop BHVs and other biomedical materials as they
would be unaffected by anti-Gal antibody-mediated injury (55).
IMMUNE INJURY
A study by Manji et al. demonstrated that steroid treatment
can substantially reduce BHVs calcification and rejection
(56). Zilla et al. identified higher levels of calcification in
bioprosthetic tissue exposed to graft-specific antibodies
(6). Rabbits were immunized with bioprosthetic aortic
tissue homogenates to generate high-titer graft-specific
antibody. Using a subcutaneous implant model, Zilla
et al. demonstrated that the binding of graft-specific
antibody to glutaraldehyde-fixed tissue enhanced the level
of calcification by circa three times. These results suggest
that antibody-mediated inflammation may contribute to
BHV calcification and that the antibody originates from
a carbohydrate source as the tissue is heavily fixed with
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glutaraldehyde to eliminate the antigenicity proteins via
cross-linking. Several studies have generated alpha-1,3-
galactosyltransferase-1 (GT1) knockout (GT1KO) pigs by
mutating pigs’ alpha-1,3-galactosyltransferase-1 (GGTA-1) to
abolish the enzyme function, where the synthesis of α-Gal
moieties on glycoproteins is blocked when homozygous (37–39).
The tissue from GTKO pigs do not bind to anti-Gal antibody
and no specific anti-Gal antibody response is elicited when
GTKO cells, tissue, and organs are transplanted (37–39).
Importantly, removal of this antigen did not eliminate GTKO
xenograft rejection, therefore suggesting that a predominantly
antibody-mediated process directed to non-Gal antigens is
present (40–43).
Previous studies involving heart or kidney xenotransplants
from GTKO pigs into baboons demonstrated that graft
rejections were mediated by antibodies bound to non-Gal
antigens and complement activation (57, 58). This suggests
that some residual xenogenic (porcine) carbohydrate antigens
exist and are reactive in primates, even in the absence of
the Gal antigen (59–63). The additional two immunogenic
endothelial cell carbohydrate antigens that have been identified
are the Hanganutziu-Deicher (H-D) or N-glycolylneuramic
acid (Neu5Gc) antigen and the Sid blood group antigen
(Sda)/CAD (produced by the porcine β1,4N-acetylgalacto-
saminyl transferase 2 (B4GALNT2) gene) (64, 65). This
carbohydrate is presented on the human embryonic kidney
cells with pig B4GALNT2. However, B4GALNT2 is present in
both human and primate. Further study is then required to
delineate the structure of these carbohydrates (59, 65). The
oligosaccharide Neu5Gc is expressed in all mammals apart
from humans and New World monkeys. A deletion in the
CAMH gene encoding the enzyme cytidine monophosphate-N-
acetyl-neuramic acid hydroxylase (CMAH), which is involved
in sialic acid synthesis, disables humans from producing
Neu5Gc (66–69). Thus, humans synthesize natural anti-Neu5Gc
antibodies (69–72), whereas Neu5Gc is present on pig valves
and pericardium (73, 74). This antibody reactivity is predicted
to contribute to clinical xenograft rejection, but it remains
challenging to confidently determine its impact due to the
lack of anti-Neu5Gc antibody in experimental NHP models
(75). Reuven et al. demonstrated the expression of Neu5Gc
in native cardiac tissues and in six commercial BHVs (76).
It is possible that removal of this polysaccharide may reduce
the antibody response and calcification. The most recently
identified xenogenic antigen is the Sda blood group, which is
predominantly expressed in human gastrointestinal epithelial
cells and at widely variant levels in human red blood cells and
other tissues and fluids. Recently, the porcine B4GALNT2 locus
has been genetically engineered and it has been found that
there are preformed NHP and human antibodies to B4GALNT2-
dependent antigens (75).
Collectively, antibody reactivity to the three aforementioned
major xenogeneic glycans, GGTA-1 (Gal), CMAH (Neu5Gc),
and B4GALNT2 (Sda) account for the majority of preformed
human anti-pig antibody reactivity (75, 77). Importantly,
it has been found that pigs engineered with mutations
that abolish the production of the three known xenogenic
glycans (triple knockout), exhibit the lowest level of antibody
reactivity in both human and baboon serum (65, 77).
However, there may be more immunogenic glycans and
proteins which are yet to be discovered. Knowledge of
all the residual non-Gal antigens could revolutionize
the field of xenotransplantation by circumventing the
immunogenicity predicament.
CONCLUSION
Transcatheter valves are currently used in the clinic with
over 100,000 TAVI procedures performed worldwide in
the past decade (33). Although they possess the advantage
of percutaneous placement, their efficacy and durability
are not well-established as they have only been briefly
active. Nevertheless, TAVI should be considered as the
biggest breakthrough in cardiac surgery technology since
the last five decades and it is shifting the paradigm
toward micro-invasive cardiac surgery. However, one may
consider transcatheter valves to be basic in terms of their
tissue because their leaflets are like currently available
surgical bioprostheses by continuing to employ the basic
technology of chemical fixation of bovine or porcine
tissues meaning they are still subject to SVD. Furthermore,
these valves still utilize dead (non-vital) tissue, ergo any
mechanical, chemical, or immunologic damage will persist and
exacerbate over time as they current cannot repair themselves
or regenerate.
Currently available prostheses are flawed and their use
is further restricted by lacking the capability of growth,
repair, remodeling, and regeneration (78). Non-regenerative
mechanical and biological prostheses fail to integrate, remodel,
or grow. This renders them unideal, particularly in pediatric
patients who will have to undergo multiple surgeries and
intervention redoes throughout their life, with an augmenting
risk of morbidity and mortality, and exacerbated quality of
life. This has been the driving force of a relatively novel
field of research known as heart valve tissue engineering
in which early approaches have concentrated on developing
new viable tissue via scaffold engineering, cells, and growth
factors with the capability to grow in the body via use of a
matrix that is seeded in vitro with harvested cells (13, 79).
Tissue engineered heart valves (TEHVs) are flexible (can adapt
and grow with age), non-thrombogenic, non-immunogenic,
durable in all age groups (not just in older groups unlike
BHVs, which will eliminate reoperations), and have ameliorated
cellular viability making them advantageous over MHV and
BHVs. However, several shortcomings (financial, logistical, and
technical) must be overcome to bring safe, feasible TEHVs into
clinical practice.
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